SkyePharma reveals doubts over US approval for Flutiform
This article was originally published in Scrip
Executive Summary
SkyePharma has expressed doubts over the likelihood of a US approval for its lead product, the combination asthma drug Flutiform (fluticasone propionate plus formoterol fumarate); following a discussion it had with the US FDA.